brazil
Home
Welcome Note
Congress Chairpersons
Organizing Committee
Faculty
Scientific Program
Industry Symposia and Activities
Programa Científico
Abstract Submission
Poster Presentation Guidelines
Poster List
Timetable
CME Accreditation
Registration
Invitation Letter
Accommodation
Hard Rock Hotel Panama Megapolis
Support & Exhibition
Information
Supporters
Exhibitors
General Information
Before you travel...
Italian Agent
Tourism in Panama
About Panama
Panama Photo Gallery
Panama Video Gallery
Previous and upcoming CODHy Congresses
Partners
Useful links
Contact Us
  Preliminary Scientific Program Print

 
Thursday March 13, 2014
19:00-20:00
Welcome Reception
 
 
Friday, March 14, 2014
 
Hall A
09:00-10:30
Plenary Session 1
Lessons to Learn from CV Outcome Studies
Chairs: J. Davidson, USA; I. Raz, Israel; D. Abouganem, Panama and
E. Mendoza, Panama

09:10-09:30

SAVOR
P. Home, UK

09:30-09:50

ORIGIN
W. Cefalu, USA

09:50-10:10

ACCORD
G. Grunberger, USA

10:10-10:30

Discussion
10:30-11:00
Coffee Break
 
Hall A
Hall B
Hall C
11:00-12:30
Session 2
Can we Achieve Durable Therapy for A1C by Triple Therapy?
Chair: N. Napoli, Italy
11:05-11:25
Should we Aim to Cure Diabetes?
N. Napoli, Italy
Triple Therapy
11:25-11:40
Yes: R.A. DeFronzo, USA

11:40-11:55
No: I. Raz, Israel
11:55-12:15
Controversies in the Treatment of Diabetic Neuropathy
A. Odriozola, Spain
12:15-12:30
Discussion
 
Session 3
Hypertension Treatment
Chair: E. Grossman, Israel and Prof. H. Shehadeh
Treatment of Hypertension in Type 2 Diabetes: Diuretics
11:05-11:20
Yes: E. Grossman, Israel
11:20-11:35
No: G. Waisman, Argentina
11:35-11:55
BP in Diabetes
G. Bakris, USA
11:55-12:15
New Oppportunities for Kidney Protection in Diabetes
A. Solini, Italy
12:15-12:30
Discussion
Session 4
Obesity
Chair: E. Gruber De Bustos, Venzuela and
S. Klein, USA
11:05-11:25
Obesity Therapy: When, Why and How?
S. Klein, USA
11:25-11:45
Overview on the New Drugs for Obesity
V. Hainer, Czech Republic
11:45-12:05
Obesity, Diabetes, Dyslipidemia and Hypertension: Translating Basic Science to Clinical Practice
E. Mendoza, Panama
12:05-12:30
Discussion
12:30-13:30
Lunch Break
13:30-15:00
Session 5
Hospitalization
Chair: S. Heller, UK
Increased Morbidity and Mortality
13:35-13:50
Yes: G. Umpierrez, USA
13:50-14:05
No: J. Mesa, Mexico
14:05-14:30
Should we Normalize Blood Glucose?
S. Heller, UK
14:30-15:00
Discussion
Session 6
Blood Glucose Targets
Chair: R. Lyra, Brazil
Glucose Targets:
Should we Change Them?
13:35-13:50
Yes: B. Itzhak, Israel
13:50-14:05
No: G.C. Aylwin, Chile
Should we start with combination therapy?
14:05-14:20
Yes: R. Lyra, Brazil
14:20-14:35
No: I. Raz, Israel
14:35-15:00
Discussion
Session 7
Bariatric Surgery
Chair: L. Van Gaal, Belgium
13:35-13:50
Bariatric Surgery and T2D: Are Their Therapeutic Weight Loss Independent Effects?
S. Klein, USA

13:50-14:05
Long Term Safety and Efficacy of Procedures
R. Cohen, Brazil
Which is the Best Procedure for Diabetic Patients?
14:05-14:20
Sleeve gastrectomy
L. Van Gaal, Belgium
14:20-14:35
Gastric Bypass
R. Cohen, Brazil
14:35-14:50
Endoscopic Therapy
F.J Lavalle-González, Mexico
14:40-15:00
Discussion
15:00-15:30
Guided Poster Tour - Poster Tour Area
15:30-17:00
Industry Plenary

17:00-17:30
Coffee Break
17:30-19:00
Industry Plenary


 
Saturday, March 15, 2014
 
Hall A
Hall B
Hall C
08:00-9:30
Session 8
Diagnosis of Diabetes and Its Complications
Chair: P. Home, UK
Should we Base Diabetes Diagnosis on A1C?
08:05-08:25
Advantages:
J. Tuomilehto, Finland
08:25-08:45
Disadvantages:
E. Standl, Germany
08:45-09:05
Why are our Current Therapies of Such Limited Efficacy?
P. Home, UK

09:05-09:30
Discussion
Session 9
Redefining the Treatment of Type 2 Diabetes
Chair: J. Davidson, USA
08:10-08:40
A New Focus on the Pathophysiology of Type 2 Diabetes
R.A. DeFronzo, USA

08:40-09:10
SGLT-2 Inhibition:
Efficiacy and Safety
S. Del Prato, Italy
09:10-09:30
Discussion
Session 10
Diabetes Algorithm
Chair: L. Litwak, Argentina
Do we Need Regional/Local Algorithms/Guidelines?
08:05-08:25
No, ADA/EASD and/or AACE are Universally Accepted
L. Litwak, Argentina
08:25-08:45
Yes, ALAD is more Appropriate
P. Aschner, Colombia
08:45-09:05
We Don't Need Them at All
L. Zagury, Brazil
09:05-09:30
Discussion
09:30-10:00
Coffee Break
10:00-11:00
Industry Plenary

11:00-12:00
Industry Plenary
Present and Future of Diabetes Therapy

12:00-13:00
Lunch Break
13:00-14:30
Session 11
Individual Approach
Chair: J. Tuomilehto, Finland and N. Barengo, Colombia
Can we Prevent Dementia/Alzheimer's Disease?
13:05-13:20
Yes: J. Tuomilehto, Finland
13:20-13:35
No: N. Barengo, Colombia
Should we quantify A1C parameters?
13:35-13:50
Yes:I. Raz, Israel
13-50-14:05
No: C. Belzarena, Uruguay
14:05-14:30
Discussion
Session 12
Emerging Therapeutic Targets for T2DM
Chair: R. DeFronzo, USA
13:05-13:25
The Role of the Kidney in Glucose Homeostasis
R.A. DeFronzo, USA
13:25-13:45
Targeting the Kidney: A Novel Approach to Diabetes Therapy
L. Van Gaal, Belgium
13:45-14:05
Safety Concerns
J. Davidson, USA
14:05-14:30
Discussion
Session 13
Can we Improve CV Outcome
Chair: P. Aschner, Colombia and A. Milech, Brazil
13:05-13:20
Diabetes and Hypoandrogenism
C. Musso, Argentina
13:20-13:35
Blood Pressure
G. Waisman, Argentina
13:35-13:50
Lipids
P. Aschner, Colombia
13-50-14:05
Sweeteners and Artificial Sweeteners
J. Mechanick, USA
14:05-14:30
Discussion
14:30-15:00
Coffee Break
15:00-16:30
Session 14
Diabetic Heart
Chair: E. Standl, Germany
15:05-15:25
Adipose Tissue
G. Márquez, Colombia
15:25-15:45
Role of Inflammation
E. Standl, Germany
15:45-16:05
Diabetes and Coronary
D. Pichel, Panama
16:05-16:30
Discussion
Session 14A
Oral Presentations
Chair: N. Napoli, Italy
New Insulin U300: Glucose Control and Hypoglycaemia in Type 2 Diabetes People on Basal Insulin and OADS
(Edition 2)
F.J. Lavalle-González, Mexico
Liraglutide Monotherapy Provides Superior Postprandial Plasma Glucose (PPG) Control After all Three Daily Meals Versus Sulphonylurea Monotherapy
A. Palacio Barrientos, Colombia
Beta 2 Microglobulin and Subclinical Atherosclerosis in Type 2 Diabetes Mellitus without Renal Impairment
H.S. Kwon, South Korea
Improvements in HBA1C and Body Weight with Liraglutide are Largely Independent of Diabetes Duration
S. Christensen, Denmark
Robust Metabolic Improvement Observed with the Endoscopic, Duodenal-Jejunal Bypass Liner: 12 Month Data in Obese Type 2 Diabetes
R. Cohen, Brazil
Session 15
Novel Therapy in Diabetes
Chair: C. Musso, Argentina and S. Del Prato, Italy
15:05-15:25
PPAR Gama in T2D
R.A. Defronzo, USA
15:25-15:45
New GLP1 Analogs
S. Del Prato, Italy
15:45-16:05
Incretin Therapy- Safety Issues
G. Grunberger, USA
16:05-16:30
Discussion
16:30-18:00

Session 16
Hypoglycemia
Chair: L. Litwak, Argentina
Should we Prevent Mild Hypoglycemia?
16:35-16:50
Yes: L. Zagury, Brazil
16:50-17:05
No: S. Heller, UK

Are There Advantages to The New Insulin Analogs?
17:05-17:20
Yes: P. Raskin, USA
17:20-17:35
No: L. Litwak, Argentina
17:36-18:00
Discussion
Session 17
Resistant Hypertension
Chair: G. Bakris, USA
Resistant Hypertension Approach
16:35-17:05
1- Pharmacological Intervention
G. Waisman, Argentina
17:05-17:35
2- Renal Denervation
G. Bakris, USA
17:35-18:00
Discussion
Session 18
DPP4 Inhibitors: an Inclusive Treatment Option
Chair: S. Del Prato, Italy
16:35-16:55
DM2 and the Next Step - the Convenience of Combination to go Beyond Metformin
P. Aschner, Colombia
16:55-17:15
The Role of DPP-4 Inhibitors for the Treatment of T2DM
A. Solini, Italy
17:15-17:35
Cardiovascular Risk Control – the Critical Aim of T2D Management
S. Del Prato, Italy
17:35-18:00
Discussion


 
Sunday, March 16, 2014
 
Hall A
08:30-10:00
Session 19
Evidence Based Guidelines: European vs. USA
Chair: S. Vinker, Israel

08:35-08:50

New guidelines for Hypertension: Europe vs. USA. What can we learn?
E. Grossman, Israel

08:50-09:05

AACE Guidelines
J. Mechanick, USA

09:05-09:10

Round Table Discussion
Chair: I. Raz, Israel

09:10-09:20

Heart Failures in Diabetes
P. Pollack, USA

09:20-09:25

Insulin
P. Home, UK

09:25-09:30

SU
L. Litwak, Argentina

09:30-09:35

DPP4 and GLP1
I. Raz, Israel

09:35-09:40

SGLT2
J. Davidson, USA

09:40-10:00

Discussion
10:00-11:30

Session 20
The Place of Insulin/Incretin Therapy in Type 2 Diabetes
Chair: E. Standl, Germany

10:05-10:20

Incretin therapy
L. Litwak, Argentina

10:20-10:35

Are Hepato-Specific insulins desirable?
P. Home, UK

10:35-10:50

Early insulin therapy
P. Raskin, USA

10:50-11:05

Late insulin therapy
E. Standl, Germany

10:50-11:05

Discussion

11:25-11:30

Closing Remarks
J. Davidson, USA; I. Raz, Israel; D. Abouganem, Panama and E. Mendoza, Panama
11:30-12:00 Closing / Refreshments

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 01/31/2016 Created by     WebStudio.co.il